Practice-Changing Viral Hepatitis Data From AASLD 2022

Source: Clinical Impact of New Viral Hepatitis Data From AASLD 2022*
November 4-8, 2022; Washington, DC
Listen to expert insights from Nancy Reau, MD, on practice-changing viral hepatitis data from AASLD 2022, including HBV therapeutics in the pipeline, HCV management strategies, HDV screening and care linkage, fatty liver disease in patients with viral hepatitis, and the role of statins in patients with liver disease.
Nancy Reau, MD
Released: December 6, 2022

In this episode, Nancy Reau, MD, shares her thoughts on the most practice-changing viral hepatitis data from AASLD 2022, including:

  • Novel therapeutics for HBV
  • HCV management strategies
  • HDV screening and linkage to care
  • Fatty liver disease in persons with viral hepatitis
  • Use of statins to decrease morbidity and mortality in persons with liver disease

Information on this Educational Activity

Faculty

Nancy Reau, MD

Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Nancy Reau, MD: consultant/advisor: AbbVie, Antios, Arbutus, Gilead Sciences, Intercept, Salix; researcher: AbbVie, Gilead Sciences, Intercept.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings